PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2010-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT00324116
- Locations
- ๐ซ๐ท
Pfizer Investigational Site, Toulouse, France
Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00322517
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, London, United Kingdom
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2010-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00321815
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Dalls, Texas, United States
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00321308
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Torino, Italy
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
Phase 3
Completed
- Conditions
- SeizuresEpilepsies, PartialEpilepsy, Complex PartialEpilepsy, GeneralizedEpilepsy
- Interventions
- Drug: PlaceboDrug: Vanquix Auto-Injector (Diazepam Injection)
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 234
- Registration Number
- NCT00319501
- Locations
- ๐บ๐ธ
Stein Life Child Neurology Medical Specialists Inc., Irvine, California, United States
๐บ๐ธLahey Clinic Medical Center, Burlington, Massachusetts, United States
๐บ๐ธMorton Plant Hospital Pharmacy, Clearwater, Florida, United States
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Phase 2
Completed
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- Interventions
- Drug: SKI-606 (Bosutinib)
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT00319254
- Locations
- ๐บ๐ฆ
Pfizer Investigational Site, Uzhgorod, Ukraine
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
Phase 4
Completed
- Conditions
- Sepsis
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00318552
- Locations
- ๐ญ๐บ
Research Site, Veszprem, Hungary
Evaluation of Pancreatic Tissue Penetration of Meronemยฎ in the Prophylaxis of Septic Complications in Severe Pancreatitis
Phase 4
Completed
- Conditions
- Pancreatitis
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00318994
- Locations
- ๐จ๐ด
Research Site, Bogota, Colombia
Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers
Phase 2
Terminated
- Conditions
- Foot Ulcer, DiabeticDiabetes Complications
- Interventions
- Drug: Vehicle gel
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00318214
- Locations
- ๐บ๐ธ
Associated Foot & Ankle Specialists, LLC, Phoenix, Arizona, United States
๐บ๐ธInnovative Medical Technologies, Los Angeles, California, United States
๐บ๐ธUniversity of Miami, Miami, Florida, United States
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
Phase 2
Terminated
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00314938
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Cardiff, United Kingdom
ยฉ Copyright 2025. All Rights Reserved by MedPath